30 August 2018
A new report by visiongain forecasts the world IVD market will reach $122.9bn in 2027. That revenue prediction and others appear in Medical Devices Leader Series - Top In Vitro Diagnostics (IVD) Companies 2017-2027: Leading IVD Companies in the US, Europe and Asia published in November 2016. Visiongain is a business information publisher and consultancy in London, UK.
Visiongain estimates that in 2016, Big Pharma companies, namely Roche, Danaher and Siemens dominated the sector accounting for 41.5% of the global IVD market with combined revenue of $25.7bn
This report analyses the leading companies operating in the in vitro diagnostics (IVD) market. It aims to provide a comprehensive review of those companies, looking at their IVD products, financial performance, deals with other drug developers and future outlooks. The study examines opportunities and challenges in the industry and market for IVD products, as well as strategies for future growth. To provide context for the company profiles, this report also contains analysis of the world IVD market. An estimate for the market size is provided for 2016, and overall market revenues are forecasted for the period 2017 to 2027. Additionally, there is an analysis of the leading IVD segments.
The report focuses on these main segments of the market:
• Clinical Chemistry
• Genetic Testing
This 185 page report provides:
• Most recent profiles of top In Vitro Diagnostic American Companies with updated revenues and forecast for the period 2017-2027
• Most recent profiles of top In Vitro Diagnostic European Companies with updated revenues and forecast for the period 2017-2027
• Most recent profiles of top In Vitro Diagnostic Asian Companies with updated revenues and forecast for the period 2017-2027
• Enhanced detail analysis of what stimulates and restrains that industry and market.
• 75 figures and 65 tables.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.